Turning the spotlight on bone marrow adipocytes in haematological malignancy and non-malignant conditions.

Autor: Austin MJ; Barts Cancer Institute, Centre for Haemato-Oncology, Queen Mary University of London, London, UK., Kalampalika F; Barts Cancer Institute, Centre for Haemato-Oncology, Queen Mary University of London, London, UK., Cawthorn WP; BHF/University Centre for Cardiovascular Science, Edinburgh Bioquarter, University of Edinburgh, Edinburgh, UK., Patel B; Barts Cancer Institute, Centre for Haemato-Oncology, Queen Mary University of London, London, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2023 May; Vol. 201 (4), pp. 605-619. Date of Electronic Publication: 2023 Apr 17.
DOI: 10.1111/bjh.18748
Abstrakt: Whilst bone marrow adipocytes (BMAd) have long been appreciated by clinical haemato-pathologists, it is only relatively recently, in the face of emerging data, that the adipocytic niche has come under the watchful eye of biologists. There is now mounting evidence to suggest that BMAds are not just a simple structural entity of bone marrow microenvironments but a bona fide driver of physio- and pathophysiological processes relevant to multiple aspects of health and disease. Whilst the truly multifaceted nature of BMAds has only just begun to emerge, paradigms have shifted already for normal, malignant and non-malignant haemopoiesis incorporating a view of adipocyte regulation. Major efforts are ongoing, to delineate the routes by which BMAds participate in health and disease with a final aim of achieving clinical tractability. This review summarises the emerging role of BMAds across the spectrum of normal and pathological haematological conditions with a particular focus on its impact on cancer therapy.
(© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: